GOOD PRODUCT + GOOD SCIENCE = WINNER
Thursday April 1, 9:37 am Eastern Time
Company Press Release
SOURCE: Gel Tech LLC
Gel Tech Scientists to Present Science Behind
ZICAM(TM) Cold Remedy
WOODLAND HILLS, Calif., April 1 /PRNewswire/ -- Gel Tech LLC, developer of the ZICAM(TM) nasal gel, a revolutionary new cold remedy, announced that its scientists will present findings from their initial research on ZICAM(TM) at the 5th International Symposium on Applied Bioinorganic Chemistry to be held April 13-17 in Corfu, Greece.
Dr. Charles B. Hensley, Chief of Research and Scientific Affairs for Gel Tech, will present a paper at the conference entitled
''THE EFFECT OF DIRECT APPLICATION OF IONIC ZINC NASAL GEL ON THE SEVERITY AND DURATION OF THE COMMON COLD'' in the Metal Based Drugs -- Metals in Medicine section of the conference.
The International Symposium of Applied Bioinorganic Chemistry, first initiated in 1989, has an international reputation as a
forum for new and significant developments in the use of inorganic materials as medicine.
Hensley said, ''It is an honor for us to be among the distinguished scientists from all over the world attending this year's
conference. We believe that it represents further recognition by the scientific community that our initial research on the effectiveness of ZICAM(TM) in treating the common cold is a significant addition to the rapidly growing body of scientific knowledge on ionic metals and the common cold.''
Dr. R. Steven Davidson, Gel Tech CEO, said, ''We are pleased that this conference provides ZICAM(TM) with international exposure as we initiate the international phase of our test marketing efforts. We have decided to proceed with plans to expand into overseas channels because of the positive response we have seen in our domestic test marketing to date.''
''Since introducing ZICAM(TM) in the United States late in the cold season, we have significant achieved distribution in major
drug and grocery chains, and we have received several reorders from both drug and grocery chains,'' added Davidson. ''We are expanding and intensifying our public relations and advertising efforts to increase distributor demand in the summer and fall in preparation for consumer demand during the next cold season.''
Dr. Davidson concluded, ''Overall, the reception we have received from both consumers and the scientific community has been very favorable, and we are on schedule with regard to additional research on the effectiveness of ZICAM(TM). I believe that the Gel Tech joint venture between Biodelivery Technologies and Gum Tech International (Nasdaq: GUMM - news) is working well and will continue to be successful as we enhance our marketing and distribution both at home and abroad.''
SOURCE: Gel Tech LLC |
